the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 
RSS Feed
Pharmaceutical
Drug Discovery
Drug Delivery System
Veterinary Medicine
Bone Disease Treatment
Obesity Treatment
Generic Drugs
OTC Drug
Prescription Drugs
Vaccines
Regulation
Cancer
Diabetes
Infection Disease
Mental Disease
Pharmaceutical Companies
Neurodegenerative Disease

* View All Categories
View Conferences
Japanese Korean Chinese
Home > Category > Pharmaceutical >

Market Research Report

Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024

Published by Visiongain Contact us : +1-860-674-8796
Published 2009/02 Content info 175 pages
Product code KT84132
Price From  US $ 2502 Order/Price list
US $ 2502 PDF by E-mail (Single User License)
US $ 5006 PDF by E-mail (Department License)
US $ 8343 PDF by E-mail (Site License)
US $ 11687 PDF by E-mail (Global Site License)
How to Order?
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Table of Contents

1. Executive Summary: Anti-Obesity Treatments 2009-2024

2. An Introduction to Obesity and Its Treatment

  • 2.1 What is Obesity?
    • 2.1.1 Fat is a Necessary Component of the Body
    • 2.1.2 Obesity is a Chronic Disease
    • 2.1.3 Body Weight is Dependent upon Several Factors
  • 2.2 How is Obesity Measured?
    • 2.2.1 Weight-for-Height Tables
    • 2.2.2 Waist Circumference
    • 2.2.3 Body Mass Index (BMI)
  • 2.3 How Serious is the Problem?
    • 2.3.1 Prevalence
    • 2.3.2 Risk Factors of Other Diseases (Co-Morbidities)
    • 2.3.3 Economic Costs
  • 2.4 Historical Causes and Lifestyle Changes
    • 2.4.1 Urbanisation, Modernisation and Economic Development
    • 2.4.2 Developed Countries and in Developing Nations
  • 2.5 Factors Causing Obesity
    • 2.5.1 Lifestyle, Environment and Diet
    • 2.5.2 Behaviour
    • 2.5.3 Psychological Factors
    • 2.5.4 Genetics
    • 2.5.5 Antecedent Illnesses and Treatments
    • 2.5.6 Other Causes
  • 2.6 Treatment of Obesity
    • 2.6.1 Lifestyle and Behavioural Changes
    • 2.6.2 Unapproved Drugs
    • 2.6.3 Alternative Therapies
    • 2.6.4 Pharmacotherapy
    • 2.6.5 Surgical Options
    • 2.6.6 Drugs have a Role in the Treatment of Obesity.
  • 2.7 Pharmacotherapy in the Treatment of Obesity
    • 2.7.1 Lipase Inhibitors
    • 2.7.2 Anorectic Drugs
    • 2.7.3 Off-Label Use of Drugs
  • 2.8 Need for Future Development in the Treatment of Obesity
    • 2.8.1 Unmet Needs and Market Potential

3. The World Market for Anti-Obesity Drugs, 2009-2024

  • 3.1 The Current Anti-Obesity Market Climate - a Potential Blockbuster Market
  • 3.2 Leading Companies in the Anti-Obesity Market
  • 3.3 Market History and the Current Situation
    • 3.3.1 The Effect of Pondimin, Redux and Public Opinion on the Anti-Obesity Market
    • 3.3.2 Rimonabant and other Cannabinoid Receptor Antagonists
    • 3.3.3 Phentermine
  • 3.4 Total Anti-Obesity Market Forecast 2009-2024
    • 3.4.1 Market Growth in 2009-2024
    • 3.4.2 Drugs after 2012
  • 3.5 Xenical Forecast 2009-2024
    • 3.5.1 Will Generic Erosion Drive Down Xenical' s Sales?
    • 3.5.2 Competition Increases with New Releases
    • 3.5.3 Will Xenical be Driven Out by Newer Rivals?
  • 3.6 Reductil/Meridia Forecast 2009-2024
    • 3.6.1 How Will Competition Affect Sales?
    • 3.6.2 Expiry of Patents in 2013
  • 3.7 Alli Forecast 2009-2024
    • 3.7.1 Early Launch-Stocking
    • 3.7.2 European Launch
    • 3.7.3 Is Alli Failing to Distinguish Itself?
  • 3.8 Dinintel Forecast 2009-2024
    • 3.8.1 Will the Rapidly Evolving Anti-Obesity Market Will Leave Dinintel Behind?
  • 3.9 Total Other Drugs Forecast 2009-2024
    • 3.9.1 Generic Competitors
    • 3.9.2 New Drug: Contrave (Orexigen)
    • 3.9.3 New Drug: Lorcaserin (Arena)
    • 3.9.4 New Drug: Qnexa (Vivus)
    • 3.9.5 New Drug: Liraglutide (Novo Nordisk)
    • 3.9.6 New Drug: Empatic/Excalia (Orexigen)
  • 3.10 Market Summary
    • 3.10.1 New Drugs and the Market
    • 3.10.2 Lack of Innovation and the Market Opportunities?
    • 3.10.3 The Problems with Anorectic Drugs
    • 3.10.4 The Problems with Lipase Inhibitors
    • 3.10.5 The Future of Anti-Obesity Treatments

4. Anti-Obesity Treatments - SWOT Analysis

  • 4.1 Strengths
    • 4.1.1 Long-Term Therapy with Anti-Obesity Drugs
    • 4.1.2 Prospects of Multiple Indications for Anti-Obesity Drugs
    • 4.1.3 Off-Label Potential and Competition
    • 4.1.4 The Anti-Obesity Market is Ready to be Revolutionised
    • 4.1.5 Failure of Rimonabant Leaves Vacuum in the Market
    • 4.1.6 New Drugs May Not Fill the Entirety of Customer Needs
  • 4.2 Weaknesses
    • 4.2.1 Limited Efficacy
    • 4.2.2 Undesirable Side-Effects Limit Market Potential of Anti-Obesity Medications
    • 4.2.3 Increased Competition by both Impending New Releases and Generic Competitors
    • 4.2.4 Regulatory Hurdles have Become Stricter - Companies Pay the Price
    • 4.2.5 Pharmacotherapy Will Never be the First Line of Treatment?
  • 4.3 Opportunities
    • 4.3.1 Rising Prevalence Drives Market Potential
    • 4.3.2 Unmet Market Needs - Can Drugs Solve this Problem?
    • 4.3.3 A Safe and Effective Anti-Obesity Treatment has Applications in Both the Clinical and Cosmetic Sectors
    • 4.3.4 How the Changing Government Agenda and the High Economic Costs of Obesity Will Drive Growth in the Anti-Obesity Market
    • 4.3.5 Diet and Exercise May be the Mainstay Treatment, but this Approach is not Always Effective
  • 4.4 Threats
    • 4.4.1 Reimbursement May Continue to be a Limiting Factor
    • 4.4.2 Long-Term Safety Issues Continue to Stunt Growth
    • 4.4.3 Opinion of Both the Public and Prescribing Bodies is Heavily Dependent upon Individual Drug Successes and Success of the Market as a Whole
    • 4.4.4 Will Healthier Lifestyles Limit the Current Need for Anti-Obesity Drugs?

5. Pipeline Developments in Anti-Obesity Treatments

  • 5.1 Treatments in Phase III
    • 5.1.1 Lorcaserin
    • 5.1.2 Qnexa
    • 5.1.3 Contrave
    • 5.1.4 Cetilistat
  • 5.2 Treatments in Phase II
    • 5.2.1 Empatic/Excalia
    • 5.2.2 Liraglutide
    • 5.2.3 Obinepitide
    • 5.2.4 Solabegron
    • 5.2.5 Tesofensine
    • 5.2.6 Velneperit
    • 5.2.7 Histalean
    • 5.2.8 Sodium Tungstate
    • 5.2.9 Serglifozin Etabonate
    • 5.2.10 Pramlintide & Metreleptin
    • 5.2.11 Hoodia gordonii Extract
    • 5.2.12 MTP Inhibitor
    • 5.2.13 TM 30339
    • 5.2.14 SLx 4090
    • 5.2.15 MK 0493
    • 5.2.16 KRP 204
    • 5.2.17 FM VP4
    • 5.2.18 AZD 2207
    • 5.2.19 CE 326597
  • 5.3 Treatments in Phase I
    • 5.3.1 Trodusquemine
    • 5.3.2 THCV
    • 5.3.3 Oral PYY3-36
    • 5.3.4 ATHX 105
    • 5.3.5 AZD 1175
    • 5.3.6 AZD 1656
    • 5.3.7 BVT 74316
    • 5.3.8 CP 404
    • 5.3.9 KD 3010
    • 5.3.10 PRX 07034
    • 5.3.11 PSN 602
    • 5.3.12 TKS 1225
    • 5.3.13 V 24343
    • 5.3.14 TTP 435
  • 5.4 Other Promising Pipeline Developments
    • 5.4.1 Melanotan
    • 5.4.2 Increasing Mitochondrial Activity to Increase Energy Expenditure
    • 5.4.3 Inhibiting the Creation of Fat Stores after Gut Absorption

6. Obesity in the Leading World Markets

  • 6.1 The Total Market for Anti-Obesity Treatments
    • 6.1.1 Drug Development Will Drive the Market
  • 6.2 US Anti-Obesity Market Forecast 2009-2024
    • 6.2.1 Patent Expiries and New Drug Releases Will Create a Turbulent Market
    • 6.2.2 Will The Market Show Uninhibited Growth During the Forecast Period?
  • 6.3 Mexico Anti-Obesity Market Forecast 2009-2024
    • 6.3.1 The Health Care System Currently Limits Treatment Accessibility
    • 6.3.2 Prevalence of Obesity Driving the Market
  • 6.4 Brazil Anti-Obesity Market Forecast 2009-2024
    • 6.4.1 Increasing Prevalence Will Force an Increase in Sales over the Forecast Period
  • 6.5 UK Anti-Obesity Market Forecast 2009-2024
    • 6.5.1 Lagging Sales Will Turn to Positive Growth in the Early Forecast Period
    • 6.5.2 Government Agenda Will Support Growth of Anti-Obesity Treatments in the UK
  • 6.6 South Korea Anti-Obesity Market Forecast 2009-2024
    • 6.6.1 Government Agenda Will Maintain High Sales
  • 6.7 Spain Anti-Obesity Market Forecast 2009-2024
    • 6.7.1 New Drug Releases and Patent Expiries
    • 6.7.2 The Market Will Show Consistent Positive Growth
  • 6.8 France Anti-Obesity Market Forecast 2009-2024
    • 6.8.1 Reimbursement will Drive Sales
  • 6.9 Total Other Countries Anti-Obesity Market Forecast 2009-2024
    • 6.9.1 Total Other Countries Sales
    • 6.9.2 The Impact of Emerging Markets
    • 6.9.3 Emerging Market: India
    • 6.9.4 Emerging Market: China

7. Experts' Views on the Main Issues in the Treatment of Obesity

  • 7.1 An Interview with Dr. Tyrberg from The Burnham Institute Diabetes and Obesity Research Centre
    • 7.1.1 The Effect of Anti-Obesity Drugs on the Obese Population
    • 7.1.2 The Cause-Effect Relationship between Diet, Obesity and Type 2 Diabetes
    • 7.1.3 Off-Label Indications and Diabetes Treatments Used to Treat Obesity
    • 7.1.4 Obesity as a Lifestyle Disease?
    • 7.1.5 The Future of Anti-Obesity Treatments and the Role Diet and Exercise Will Play
    • 7.1.6 The Role of Pharmaceutical Companies, Ethics and the Cosmetic Use of Anti-Obesity Treatments
    • 7.1.7 Unmet Medical Needs in the Treatment of Obesity
    • 7.1.8 The Future of the Anti-Obesity Market
  • 7.2 Commentaries and Views from Other Experts in the Field
    • 7.2.1 The Most Important Unmet Medical Needs in the Treatment of Obesity
    • 7.2.2 The Future of Anti-Obesity Treatment
    • 7.2.3 Funding of Anti-Obesity Treatments
    • 7.2.4 The Anti-Obesity Market in Developing Nations
    • 7.2.5 Concluding Thoughts

8 .Conclusions

  • 8.1 Obesity is a Chronic Disease with Serious Health Implications
  • 8.2 The Prevalence and Economic Costs of Obesity
  • 8.3 The Modern Lifestyle has Contributed Significantly to Obesity
  • 8.4 Obesity is Caused by a Complex Interplay of Factors
  • 8.5 Obesity Treatments and the Role of Pharmaceuticals
  • 8.6 The Unmet Needs and Market Potential for Anti-Obesity Treatments
  • 8.7 The Anti-Obesity Market Will Expand from 2009-2024
  • 8.8 The Main Drivers and Restraints of the Anti-Obesity Market
  • 8.9 Geographical Overview of the Anti-Obesity Market
  • 8.10 Outlook for the Future

Appendices

  • Appendix 1: Conditions Associated with Obesity
  • Appendix 2: Bariatric Surgery Options
  • Appendix 3: About visiongain
  • Appendix 4: Visiongain Report Evaluation Form

List of Tables

  • Table 2.1 - BMI Classification Bands
  • Table 2.2 - Obesity Prevalence Amongst US Adults 1991-2007
  • Table 3.1 - Leading Anti-Obesity Drugs in Sales ($m), Market Share (%) and Growth (%), 2007
  • Table 3.2 - Leading Companies for Anti-Obesity Drugs in Sales ($m) and Market Share (%), 2007
  • Table 3.3 -Total Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 3.4 - Total Anti-Obesity Market CAGR Values (%), 2009-2024
  • Table 3.5 - Xenical Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 3.6 - Xenical CAGR Values (%), 2009-2024
  • Table 3.7 - Reductil/Meridia Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 3.8 - Reductil/Meridia CAGR Values (%), 2009-2024
  • Table 3.9 - Alli Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 3.10 - Alli CAGR Values (%), 2009-2024
  • Table 3.11 - Dinintel Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 3.12 - Dinintel CAGR Values (%), 2009-2024
  • Table 3.13 - Total Other Drugs Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 3.14 - Total Others Drugs CAGR Values (%), 2009-2024
  • Table 4.1 - SWOT Chart of the Anti-Obesity Market, 2009-2024
  • Table 5.1 -The Anti-Obesity Pipeline 2009
  • Table 6.1 - US Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 6.2 - US Anti-Obesity Market CAGR Values (%), 2009-2024
  • Table 6.3 - Mexico Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 6.4 - Mexico Anti-Obesity Market CAGR Values (%), 2009-2024
  • Table 6.5 - Brazil Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 6.6 - Brazil Anti-Obesity Market CAGR Values (%), 2009-2024
  • Table 6.7 - UK Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 6.8 - UK Anti-Obesity Market CAGR Values (%), 2009-2024
  • Table 6.9 - South Korea Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 6.10 - South Korea Anti-Obesity Market CAGR Values (%), 2009-2024
  • Table 6.11 - Spain Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 6.12 - Spain Anti-Obesity Market CAGR Values (%), 2009-2024
  • Table 6.13 - France Anti-Obesity Market CAGR Values (%), 2009-2024
  • Table 6.14 - France Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 6.15 - Total Other Countries Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
  • Table 6.16 - Total Other Countries Anti-Obesity Market CAGR Values (%), 2009-2024
  • Table A2.1 - Bariatric Surgery Options

List of Figures

  • Figure 2.1 - Obesity Prevalence Amongst US Adults 1991-2007
  • Figure 3.1 - Leading Anti-Obesity Drugs Sales ($m), 2007
  • Figure 3.2 - Leading Anti-Obesity Drugs Market Share (%), 2007
  • Figure 3.3 - Leading Companies of Anti-Obesity Drugs Sales ($m), 2007
  • Figure 3.4 - Leading Companies Anti-Obesity Market Share (%), 2007
  • Figure 3.5 - Total Anti-Obesity Market Sales ($m), 2009-2024
  • Figure 3.6 - Xenical Sales ($m), 2009-2024
  • Figure 3.7 - Reductil/Meridia Sales ($m), 2009-2024
  • Figure 3.8 - Alli Sales ($m), 2009-2024
  • Figure 3.9 - Dinintel Sales ($m), 2009-2024
  • Figure 3.10 - Total Other Drugs Sales ($m), 2009-2024
  • Figure 3.11 - All Drugs Market Share (%), 2009-2024
  • Figure 6.1 - Total Anti-Obesity Market Sales ($m), 2009-2024
  • Figure 6.2 - US Anti-Obesity Market Forecast Sales ($m), 2009-2024
  • Figure 6.3 - Mexico Anti-Obesity Market Forecast Sales ($m), 2009-2024
  • Figure 6.4 - Brazil Anti-Obesity Market Forecast Sales ($m), 2009-2024
  • Figure 6.5 - UK Anti-Obesity Market Forecast Sales ($m), 2009-2024
  • Figure 6.6 - South Korea Anti-Obesity Market Forecast Sales ($m), 2009-2024
  • Figure 6.7 - Spain Anti-Obesity Market Forecast Sales ($m), 2009-2024
  • Figure 6.8 - France Anti-Obesity Market Forecast Sales ($m), 2009-2024
  • Figure 6.9 - Total Other Countries Anti-Obesity Market Forecast Sales ($m), 2009-2024
  • Figure 6.10 - Anti-Obesity Combined Country Forecast Sales ($m), 2009-2024
  • Figure 6.11 - Anti-Obesity Market Country Market Share Forecast (%), 2009-2024
  • Figure 8.1 - Total Anti-Obesity Market Sales ($m), 2009-2024
  • Figure 8.2 - Anti-Obesity Drugs Forecast by Market Share (%), 2009-2024
  • Figure 8.3 - Anti-Obesity Combined Country Forecast Sales ($m), 2009-2024
  • Figure 8.4 - Anti-Obesity Market Country Market Share Forecast, 2009-2024

Companies Listed

  • 7TM Pharma
  • Abbott
  • Ache Laboratories
  • Actavis
  • Alizyme
  • American Home Products
  • Amylin
  • Arena
  • AstraZeneca
  • Athersys
  • Barcelona University
  • Bayer
  • Biovitrum
  • Bristol-Myers Squibb
  • Clinuvel
  • Compellis
  • Council for Scientific and Industrial Research
  • Duke University
  • Eli Lilly
  • EMEA
  • Emisphere
  • EMS
  • Epix
  • FDA
  • Forbes Medi-Tech
  • Gate Pharmaceuticals
  • Genaera
  • GlaxoSmithKline
  • Graceway Pharma
  • GW Pharmaceuticals
  • Han Wha
  • Hanmi
  • Inova Pharma
  • Johnson & Johnson
  • Kalypsys
  • Kissei
  • Kyorin
  • Louisiana State University
  • Medley
  • Merck & Co.
  • NeuroSearch
  • Novartis
  • Novo Nordisk
  • Nycomed Pharma
  • OBEcure
  • Orexigen
  • OSI Pharmaceuticals
  • Pfizer
  • Phytopharm
  • Roche
  • Sanofi-Aventis
  • Shionogi
  • Sirtris Pharmaceuticals
  • Solvay
  • Surface Logix
  • Takeda
  • Teva
  • The Burnham Institute
  • Transition
  • TransTech
  • URL Pharma
  • Vernalis
  • Vivus
  • Wyeth Pharmaceuticals
Related Report
Adult Obesity and Diabetes - US - August 2009 Bariatric (Obesity) Surgical Devices Global Weight Loss and Diet Management (2009 - 2014) Obesity Market Forecast Pipeline and Commercial Insight: Obesity - The $11 billion market that never was
Back to Top
Please inform me when related publications are released
InfoWatch

| FAQ | About The Infoshop | Policies | Site Map |
US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.